A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Skin Cancer (Non-Melanoma)
18 Years and older, Male and Female
The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety.
This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent
or persistent Cutaneous T-Cell Lymphoma (CTCL). The study will consist of an initial lead-in
phase (in which a dose of E7777 will be selected), followed by the Main Study. Participants
will move through three phases while on study: Pretreatment Phase, Treatment Phase, and
Extension Phase and a Follow-up Period.